SOLIDARITY
2021
WHO SOLIDARITY Trial
In 11,266 hospitalised COVID-19 patients across 405 hospitals, remdesivir, hydroxychloroquine, lopinavir or interferon did not reduce in-hospital mortality versus standard care.
Result
Primary endpoint: In-hospital mortality
No clear mortality benefit for any agent.
- Subtopic
- Antivirals
- Design
- Adaptive open-label RCT, WHO
- Enrolled
- 11,330 patients
- Relevance
- Important: one of several pillars.
- Source
- WHO Solidarity Trial Consortium. N Engl J Med. 2021;384(6):497-511.doi 10.1056/NEJMoa2023184
Discussion & critique
Pragmatic global RCT; tempered remdesivir enthusiasm and ended hydroxychloroquine.